Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Response and resistance to first and second generation TRK inhibitors in an NTRK1-driven sarcoma

ABSTRACT: Response and resistance to first and second generation TRK inhibitors in an NTRK1-driven sarcoma

PROVIDER: PRJNA548088 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9257360.fastq.gz	Fastqsanger.gz
	SRR9257361.fastq.gz	Fastqsanger.gz
	SRR9257362.fastq.gz	Fastqsanger.gz
	SRR9257357.fastq.gz	Fastqsanger.gz
	SRR9257358.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Response and resistance to first and second generation TRK inhibitors in an NTRK1-driven sarcoma

Project description:We report here a patient with a TPM3-NTRK1 translocated sarcoma who developed resistance to larotrectenib arising from the p.G595R solvent-front substitution. The patient was treated with LOXO-195 with initial response followed by subsequent resistance. Molecular profiling of the resistant tumor identified a KRAS p.G12V substitution, with associated activation of KRAS signaling and immune infiltration into the tumor. Following cytoreductive surgery to remove the resistant lesion, the patient’s disease has continued to respond to LOXO-195.

2022-05-23 | GSE132439 | GEO

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-type Non-Small Cell Lung Cancer

Project description:Treatment of non-small cell lung cancer (NSCLC) has drastically changed in recent years owing to the robust anti-cancer effects of immune-checkpoint inhibitors (ICI). However, only 20% of NSCLC patients benefit from ICIs, highlighting the need to uncover the mechanisms mediating resistance. By analyzing the overall survival (OS) and mutational profiles of 424 NSCLC patients who received ICI treatments between 2015 and 2021, we determined that patients carrying a loss of function mutation in neurotrophic tyrosine kinase receptor 1 (NTRK1) had a prolonged OS compared to patients with wild-type NTRK1. Notably, suppression of the NTRK1 pathway by knockdown or Entrectinib treatment significantly enhanced ICI efficacy in mouse NSCLC models. RNA sequencing of tumors and NTRK1 knockdown cell lines were performed to demonstrates the role for NTRK1 signaling.

2024-08-20 | GSE274960 | GEO

scATAC-seq of first and second-trimester human gonads

Project description:scATAC-seq of first and second-trimester human gonads

| PRJEB52512 | ENA

RNA-seq of human first and second trimester placenta

Project description:RNA-seq of human first and second trimester placenta

| PRJEB38810 | ENA

scATAC-seq of first and second trimester human reproductive tract

Project description:scATAC-seq of first and second trimester human reproductive tract

| PRJEB95780 | ENA

Spatial transcriptomics (Visium) of first and second-trimester human gonads

Project description:Spatial transcriptomics (Visium) of first and second-trimester human gonads

| PRJEB54898 | ENA

multiomic snRNAseq/snATACseq of first and second-trimester human gonads

Project description:multiomic snRNAseq/snATACseq of first and second-trimester human gonads

| PRJEB64599 | ENA

scRNA-seq of first and second trimester human reproductive tract

Project description:scRNA-seq of first and second trimester human reproductive tract

| PRJEB95773 | ENA

Multiomic snRNAseq/snATACseq of first and second-trimester human gonads

Project description:Multiomic snRNAseq/snATACseq of first and second-trimester human gonads

| PRJEB52752 | ENA

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer

Project description:The identification and clinical validation of cancer driver genes are essential to accelerate the translational transition of cancer genomics, as well as to find clinically confident targets for the therapeutic intervention of cancers. Here we identified recurrent LMNA-NTRK1 and TPM3-NTRK1 fusions in Korean patients with colon cancer (3 out of 147, 2%) through next-generation RNA sequencing (RNA-seq). NTRK1 fusions were mutually exclusive oncogenic drivers of colon cancer that were accompanied with in vitro potential of colony formation and in vivo tumorigenicity comparable to KM12, a human colon cancer cell line harboring TPM3-NTRK1 fusion. NTRK1-encoded TrkA protein was prevalent in 11 out of 216 Korean (5.1%) and 28 out of 472 Chinese patients (5.9%) from independent cohorts, respectively. The expression level of TrkA was significantly correlated with NTRK1 fusion (p = 0.0192), which was verified by a fluorescence in situ hybridization (FISH). Korean patients with TrkA-positive colon cancer had a marginal but significant shorter overall survival time than TrkA-negative colon cancer [hazard ratio (HR) = 0.5346, 95% confidential interval (CI) = 0.2548-0.9722, p = 0.0411]. In addition, KM12 cell line was sensitive to selective TrkA inhibitors. These results demonstrate that NTRK1 fusion is granted as a clinically relevant target for therapeutic intervention of colon cancer.

2021-07-31 | GSE180440 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data